Product news

Share this article:
FDA has approved Takeda's Uloric (febuxostat), indicated for the chronic management of hyperuricemia in patients with gout. The once-daily product represents the first new treatment option in more than 40 years, according to a company release.
 
Device manufacturer C.R. Bard announced an FDA pre-market approval for its LifeStent FlexStar and FlexStar XL Vascular Stent Systems. The devices are approved for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries, and are marketed by Bard's peripheral vascular division, in Tempe, AZ. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.